Immunotherapy improves survival by almost 30% in the most aggressive breast cancer


    Immunotherapy improves survival in the most aggressive breast cancer by almost 30%

    La Adding an immunotherapy drug, pembrolizumab, to first-line chemotherapy improves overall survival by 27% in patients with a type of advanced triple negative breast cancer, according to the updated results of a study led by the International Breast Cancer Center (IBCC).

    This center leads the international study KEYNOTE-355, whose latest results are published this Thursday by the scientific journal The New England Journal of Medicine (NEJM).

    The latest data corroborate that the addition of the immunotherapy drug pembrolizumabTreatment with first-line chemotherapy improves the overall survival of patients with advanced triple-negative breast cancer with PD-L1 expression (a biomarker that indicates that the defenses are slowed down) by 27%. /p>

    Against the worst prognosis of breast cancer

    The first results of this study, led by the director of the IBCC, Javier Cortés, were presented at the congress of the American Society of Clinical Oncology 2020 (ASCO 2020).

    Subsequently, at the congress of the European Society for Medical Oncology (ESMO Congress 2021), more mature data on overall survival were presented, which led to the approval by the European Medicines Agency. in October 2021.

    “This is very relevant news because triple negative breast cancer is currently the one with the worst prognosisand one of the subtypes in which oncologists are most interested in finding new therapies that improve the survival and quality of life of our patients”, Cortés highlighted.

    The cancer Triple-negative breast cancer – so called because the cells do not contain estrogen or progesterone receptors nor do they produce excess HER2 protein – accounts for about 15% of all cancers. breast tumors that are diagnosed.

    It is a very aggressive tumor subtype that spreads rapidly and has the worst overall survival rates when the patient is in advanced stage of disease.

    The phase III KEYNOTE-355 study was It has been carried out in 209 centers in 29 countries and a total of 847 patients with advanced triple-negative breast cancer have been included, regardless of whether or not they expressed the PD-L1 biomarker.

    After a follow-up of 44.1 months, the latest data from the KEYNOTE-355 study have shown that adding pembrolizumab to chemotherapy treatment statistically significantly increases survival by almost 7 months in patients with advanced triple-negative breast cancer expressing PD-L1.

    The median overall survival for patients who received chemotherapy and pembrolizumab was 23 months compared with 16 months. .1 months in the group that received chemotherapy plus a placebo.

    Guide to covid

    • These are the symptoms of the omicron variant of the coronavirus
    • What is stealthy omicron and what are its symptoms?
    • When does omicron stop spreading?
    • XE variant: this is the new super-contagious mutation of covid
    • Coronavirus: this is the situation in Catalonia
    • Hyperesthesia: what is this symptom of the omicron variant?


    Please enter your comment!
    Please enter your name here